Publications by authors named "Joss Adams"
A man in his 80s was undergoing immunotherapy with pembrolizumab, an anti-PD-1 monoclonal antibody, following his diagnosis of adenocarcinoma of primary lung origin. 24 weeks into treatment, the patient reported experiencing loose stools associated with malaise and poor appetite but no further symptoms. This progressed in frequency and a clinical diagnosis of grade 2 immune checkpoint inhibitor colitis was made.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates immune checkpoint inhibitor (ICI)-colitis to understand its causes and similarities to idiopathic ulcerative colitis, aiming to find new treatment targets.
- Key findings reveal that activated CD8 T cells are predominant in ICI-colitis, and their activation is linked to the severity of the condition, differing from the patterns seen in ulcerative colitis.
- The research highlights that targeting these activated CD8 T cells with the JAK inhibitor tofacitinib shows promise as a treatment for ICI-colitis.